Other Income / (Expense) - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
Sep. 30, 2022	Sep. 30, 2021
Gain on sale of Investments	$ 11,682	$ 0
CCXI [Member]
Gain on sale of Investments	37,200
Changzhou Eminence Biotechnology [Member]
Gain on sale of Investments	$ 11,700

Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(9)(a))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(g))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(7)(c))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(a))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Name:	us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration